# First Human Administration of Senolytic Immunotherapy to Fight Cellular Aging Announced by Immorta Bio

- Source: PR Newswire M&A
- Published: 2026-11-02T13:32:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/first-human-administration-of-senolytic-immunotherapy-to-fight-cellular-aging-announced-by-immorta-bio-302926449.html
- Canonical: https://groundlevelnews.com/story/first-human-administration-of-senolytic-immunotherapy-to-fight-cellula-3319bc/

First patient receives SenoMune™-0257, a pioneering immunotherapy designed to eliminate aging cells and advance treatment of age-related diseases MIAMI, Nov. 2, 2026 /PRNewswire/ -- Immorta Bio, Inc. today announced the first human administration of SenoMune™-0257, an investigational...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._